Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?

0.25 CME
0.25 CNE
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Ace-The-Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?


Provided by AACME logo

This educational activity is supported by an educational grant from AbbVie.

Release date: February 23, 2023
Expiration date:  February 23, 2024
Estimated time to complete: 0.25 hours
Activity URL:

Activity Description

Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.

Key questions to be addressed within this activity include:

What are the available approved agents for patients with newly diagnosed and relapsed AML and their implications for patient selection, and clinical care?
How does the clinical care team evaluate patients with AML receiving treatment with recently approved agents to identify early indications of adverse events and implement appropriate interventions?
What should the care team outline for the patient and family/caregiver to prevent infection, identify signs of bleeding, and perform other assessments to improve early identification and management of adverse events?

The activities in this series are designed for the hematology care team (physician, APP, nurse, pharmacist) engaged in the care of patients with AML.

Faculty Educators

Naval G. Daver, MD
Associate Professor
Director, Leukemia Research Alliance
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Annie Lattanzio Hale, MSN, RN, OCN
Oncology Nurse Navigator
Ann B. Barshinger Cancer Institute
Lancaster, PA

Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington Cancer Center
Lexington, KY

Learning Objectives

After participating in the activity, learners should be better able to:

  • Identify and recognize key molecular and cytogenetic markers and their impact on the prognosis of a patient with AML
  • Review and appraise recently approved targeted agents for patients with newly diagnosed and relapsed AML and their place in therapy
  • Identify key warnings and adverse drug reactions associated with new therapies and select an appropriate multidisciplinary management strategy
  • Consider challenges with your care team to treating patients during the COVID-19 pandemic and measures that can be implemented to reduce patients’ risk of infection while upholding evidence-based medicine

Accreditation and Credit Designation

Joint provider logo

In support of improving patient care, American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM logo

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  


This activity provides 0.25 ACPE contact hours (0.025 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-23-006-H01-P. Knowledge

Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this enduring educational activity for 0.25 ANCC contact hours (0.25 pharmacotherapeutic contact hours).

Other members of the care team will receive a certificate of participation.


According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educators

Naval G. Daver, MD
Dr. Daver discloses the following relevant financial relationships with ineligible companies:
Advisory Board/Consultant: Daichi-Sankyo, Bristol Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, Agios
Grant/Research Support: Daiichi-Sankyo, Bristol Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Hanmi, Trovagene, FATE Therapeutics, Novimmune, Glycomimetics

Annie Lattanzio Hale, MSN, RN, OCN
Ms. Lattanzio-Hale discloses the following relevant financial relationships with ineligible companies:
Advisory Board/Consultant: Sierra Oncology*

Megan May, PharmD, BCOP
Dr. May discloses no relevant financial relationships with ineligible companies.

Independent Clinical Reviewer

Val Adams, PharmD
Dr. Adams discloses the following relevant financial relationships with ineligible companies:
Advisory Board/Consultant: Bristol Myers Squibb*
Grant/Research Support: Bristol Myers Squibb*

*financial relationship has ended

Planning Committee

John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD, Natalie Kirkwood RN, BSN, JD, and Paul J. Miniter, MS, American Academy of CME: No relevant relationships with ineligible companies to disclose.

Off-label-disclosure: This activity mentions drugs that are not currently indicated in AML.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE/CPE/CE credit and for physicians to be eligible to earn ABIM MOC points for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique ABIM ID when completing the activity evaluation. Physicians who do not know their ABIM ID can log in to the ABIM website at — your ABIM ID will appear next to your name.

By claiming MOC points, you are agreeing to allow your participation completion information to be shared with the ACCME and the ABIM. Your points will be automatically submitted to the ABIM on your behalf; please allow 6-8 weeks for your points to display on the ABIM website.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


For more information about the American Academy of CME privacy policy, please access


For any questions, please contact:


© 2023. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).